Interstitial Lung Disease Secondary to Autoimmune Disorders: Recent Advances and Novel Perspectives
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".
Deadline for manuscript submissions: 25 November 2025 | Viewed by 594
Special Issue Editors
Interests: interstitial lung disease; autoimmune systemic diseases; Sjögren’s disease; systemic vasculitis; lung involvement
Interests: interstitial pneumonia with autoimmune features (IPAF); interstitial lung diseases associated with systemic autoimmune diseases; rheumatic diseases
Special Issues, Collections and Topics in MDPI journals
Interests: interstitial lung disease; systemic vasculitis; autoimmune systemic diseases; Sjögren’s disease; lung involvement; COVID-19 pneumonia
Special Issue Information
Dear Colleagues,
Interstitial lung disease (ILD) has a high prevalence across a wide range of autoimmune systemic disorders (AIDs). ILD development carries a high burden of mortality for AID patients, often representing the leading organ involvement and influencing therapeutic strategies. On the other hand, there is growing awareness that ILD may be the first (and sometimes the sole) clinical manifestation of an AID, posing a significant diagnostic challenge.
AID-related ILD encompasses a wide spectrum of pulmonary phenotypes, ranging from chronic fibrosing conditions to rapidly progressive, highly inflammatory pictures. Anticipating the trajectory of ILD and discriminating between ongoing fibrosis and inflammation may be key for the choice of the most appropriate treatment regimen.
In this complex scenario, the aim of this Special Issue is to collect new evidence regarding the diagnosis, phenotyping, and outcome prediction of lung involvement secondary to autoimmune etiologies, as well as studies investigating the complex pathogenetic pathways underlying ILD development and new potential therapeutic targets.
Original studies, brief reports on original data, and systematic and narrative reviews are welcome. Submitted studies may include (but are not necessarily limited to) the following topics:
- Diagnostic and multidisciplinary approach to new-onset ILD patients;
- Phenotypic stratification of AID-ILD;
- Novel biomarkers for ILD prediction, diagnosis, and prognostic stratification in AID patients;
- New imaging techniques for ILD assessment including lung ultrasound and HRCT analysis with AI-based software;
- Traditional and novel therapeutic approaches to AID-ILD;
- Cellular and molecular pathogenetic mechanisms underlying ILD development and progression.
We would be glad to receive your valuable contributions.
Dr. Gaetano La Rocca
Prof. Dr. Gianluca Sambataro
Dr. Francesco Ferro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- interstitial lung disease
- lung involvement
- connective tissue diseases
- rheumatoid arthritis
- systemic vasculitis
- radiomics
- lung ultrasound
- biomarkers
- pathogenetic immunological pathways
- therapeutic targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
